Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105001 | 0.92 | ALDH1A1 (0.32) | CA1CA2TSHRALDH1A1 | |
| SCHEMBL7103503 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL7102305 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL7101445 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL7098993 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL7098154 | 0.90 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL15368919 | 0.84 | CA1 (0.31) | CA1CA2TSHRTDP1ALDH1A1 | |
| SCHEMBL7103682 | 0.83 | — | — | |
| SCHEMBL7771893 | 0.78 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL2258455 | 0.77 | TSHR (0.35) | CA1CA2TSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-3860984-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070088-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-09 | — | — | WO | disclosed |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2935274-B1 | 3-OXO-2,3,5,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRIMIDINE DERIVATIVES FOR THE TREATMETN OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2018-10-03 | — | — | EP | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9828382-B2 | Pyrimidinone compounds as human neutrophil elastase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828382-B2 | Pyrimidinone compounds as human neutrophil elastase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-28 | — | — | US | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1020443-B1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | AZWELL INC (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
| US-6172228-B1 | Process for producing piperazinesulfonamide derivatives and salts thereof | AZWELL INC. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1020443-A1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | Azwell Inc. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0211236-A1 | 7-Oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-02-25 | — | — | EP | disclosed |
| EP-0026611-B1 | ANTIBACTERIAL SULPHONAMIDES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1984-02-01 | — | — | EP | disclosed |
| US-4312867-A | USED FOR HUMANS AND IN VETERINARY MEDICINE | BEECHAM GROUP LIMITED (GB) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | CA1 3556/4885CA2 1910/4885TSHR 521/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | CA1 4553/4885CA2 4418/4885TSHR 1187/4885 |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | CA1 4706/4885CA2 4847/4885TSHR 3371/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | CA1 4309/4885CA2 4184/4885TSHR 1226/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | CA1 4706/4885CA2 4847/4885TSHR 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.